Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Plays Down Reliance On TIGIT And Alzheimer’s Drugs For Growth

Company Boasts 51 Late-Stage Candidates

Executive Summary

Pharma chief Bill Anderson was optimistic about growth prospects, and downplayed Roche’s reliance on two near-term readouts at an investor day in London.

You may also be interested in...



Ups And Downs Of Anti-TIGIT Development

Once heralded with optimism, the class of anti-TIGIT molecules has since fallen out of favor, plagued by a succession of disappointing findings.

Roche CEO Outlines M&A Criteria

Every year, Roche looks at “more than 1,000 companies and 99.9% of the time, we say no,"  says CEO Thomas Schinecker, though he stressed that the Swiss group is open to deals of any size.

Five Clinical Trial Misses Of 2022

Drug makers have sought to branch into new frontiers of drug development in areas like cancers and neurology, but not all of them have been success stories. Here, Scrip looks at some of the more notable clinical trial misses of last year.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147042

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel